Lurbinectedin (Zepzelca) – How often should you monitor side‑effects?
| Parameter | Why it matters | Typical monitoring schedule | What to look for |
|-----------|----------------|---------------------------|------------------|
| Complete Blood Count (CBC) + Absolute Neutrophil Count (ANC) | Lurbinectedin causes bone‑marrow suppression—neutropenia, anemia, and thrombocytopenia are the most common cytopenias. | Baseline before the first infusion.
Every cycle (usually every 3 weeks, i.e., on day 1 of each treatment cycle). | ANC < 500 /µL → hold dose or reduce; platelets < 75 k/µL → hold/reduce; anemia that causes fatigue or requires transfusion. |
| Liver Function Tests (AST, ALT, ALP, bilirubin) | Hepatotoxicity is a known risk; elevations ≥ 3× upper limit of normal (ULN) may require dose adjustment or discontinuation. | Baseline before first cycle.
Every cycle (day 1). Some protocols add a repeat LFT on day 8 of cycle 1, but day‑1 is the minimum. | ALT/AST > 3× ULN or bilirubin > 2× ULN → pause or reduce dose; persistent elevation → consider stopping. |
| Renal function (Serum creatinine, eGFR) | While not a primary toxicity, impaired renal function can alter drug clearance and increase other toxicities. | Baseline before first cycle.
Every cycle (day 1) if eGFR < 30 mL/min. | Declining eGFR or rising creatinine → dose adjustment. |
| Physical exam + symptom review | Peripheral neuropathy, mucositis, GI upset (nausea, vomiting), fatigue, and infection signs are frequent. | At every clinic visit (i.e., before each infusion). | New or worsening neuropathic pain, mucosal ulcers, fever > 38 °C, or any bleeding. |
| Electrocardiogram (ECG) | Rare cardiac events have been reported; baseline ECG is recommended. | Baseline; repeat if clinically indicated (e.g., new arrhythmia). | New arrhythmia, QT prolongation. |
Key points
1. Every 3‑week cycle: CBC + ANC and LFTs are the minimum.
2. If you develop cytopenias: The drug label recommends delaying the next cycle until ANC ≥ 1,500 /µL (or the specified threshold) and platelets ≥ 75 k/µL, then resume at the next available dose level or with a reduced dose.
3. Liver toxicity: If ALT/AST rise to > 3× ULN or bilirubin > 2× ULN, consider dose reduction (e.g., from 1.2 mg/m² to 1.0 mg/m²) or discontinuation if levels persist.
4. Peripheral neuropathy: Grade ≥ 2 neuropathy warrants dose reduction or discontinuation.
5. Infection vigilance: Any fever, chills, or sore throat should prompt evaluation for neutropenic fever.
Practical checklist for patients
- Before each infusion: Bring your latest CBC, ANC, LFTs, and renal panel if ordered.
- After infusion: Monitor for signs of infection (fever, chills) or bleeding. Report any new pain, numbness, or GI symptoms promptly.
- Between cycles: If you notice any new symptoms, call your oncology team even if labs are pending.
---
Bottom line: The standard of care is to check CBC/ANC and LFTs before every 3‑week cycle of lurbinectedin, and to perform a physical exam with symptom review at each visit. Adjustments to the schedule or dose are made based on the severity of any detected toxicities. If you have specific concerns or are on a different schedule (e.g., 4‑week cycles), your oncology team will tailor the monitoring plan accordingly.